Chakravarthy MV, Elliott MA, Acosta L, Sonnenberg GE, et al. Efficacy and safety of CT-868, a novel, fully biased, dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double-blind, randomized placebo controlled phase 2 trial. Diabetes Obes Metab 2025 Aug 5. doi: 10.1111/dom.70006.
PMID: 40762050